Aparicio Gallego Emilia, Castilla Peris Carmen, Díez García María Teresa, Dorado Araceli, Mendoza Genoveva, Núñez Fernández José María, Pascual Ríos Jesús
DUE. C.S. Burjasot II, Valencia.
Rev Enferm. 2005 Dec;28(12):49-55.
Evaluate the behavior of a Sureskin II hydrocolloid dressing in the treatment of acute and chronic dermal ulcers in daily clinical practice.
By means of an observational, multi-centric, prospective, open study of a series of clinical cases on patients afflicted by acute and chronic ulcers. This study lasted through 20 dressing changes or until the ulcer was cured. During the initial visit, the characteristics of the lesion were evaluated; in continuation, the evolution of a lesion as dressings were changed was evaluated; and during the final visit, the professional team evaluated the final traits of the lesion along with the overall behavior of the dressing applied.
This study evaluated 1080 patients whose average age was 72.3 years. At the conclusion of this study the investigators noticed that the size of these ulcers had significantly reduced from the start to the end of treatment. Epithelization increased from 43.2 to 71.9%. 98.3% of patients in this study considered this dressing brand easy to apply Seepage of exudation diminished from 31.77 to 14.6%. The presence of maceration, erythema and eczema also reduced from 29.2 to 12.5%, from 37.6 to 13.1% and from 9.7 to 6.3% respectively. The symptoms of infection or inflammation dropped from 22.6 to 7.6%. Patients' complaints of pain when their dressings were changed dropped 29.4%. 90.7% of these patients stated this treatment alleviated their symptoms and allowed them to carry on their daily activities in a normal fashion.
The results of this study show that the use of Sureskin II is effective, therefore making it a first choice therapeutic option for treating patients suffering from acute and chronic dermal ulcers.
在日常临床实践中评估SureSkin II水胶体敷料治疗急慢性皮肤溃疡的效果。
通过对一系列急慢性溃疡患者进行观察性、多中心、前瞻性、开放性临床病例研究。本研究持续进行20次换药或直至溃疡治愈。在初次就诊时，评估病变特征；接着，在换药过程中评估病变的演变；在末次就诊时，专业团队评估病变的最终特征以及所应用敷料的整体效果。
本研究评估了1080例患者，平均年龄为72.3岁。在本研究结束时，研究人员注意到这些溃疡的大小从治疗开始到结束有显著减小。上皮化率从43.2%提高到71.9%。本研究中98.3%的患者认为该品牌敷料易于应用。渗出液渗漏从31.77%降至14.6%。浸渍、红斑和湿疹的发生率也分别从29.2%降至12.5%、从37.6%降至13.1%和从9.7%降至6.3%。感染或炎症症状从22.6%降至7.6%。患者换药时的疼痛主诉下降了29.4%。90.7%的患者表示这种治疗缓解了他们的症状，使他们能够正常进行日常活动。
本研究结果表明，使用SureSkin II是有效的，因此使其成为治疗急慢性皮肤溃疡患者的首选治疗方案。
